{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:17:19Z","timestamp":1785172639176,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01607-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:09:29Z","timestamp":1764954569000},"page":"563-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6395","authenticated-orcid":false,"given":"Rosa","family":"Izu-Belloso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gainza-Apraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Meruelo-Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Arevalo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Navajas-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Orbea-Sope\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pascual-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez-Buil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadea","family":"Braceras-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Arrue-Michelena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Gonz\u00e1lez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Ramos-Bare\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez de Salinas- Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"2","key":"1607_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1607_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, et\u00a0al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1607_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000\u20136.","journal-title":"Eur Heart J"},{"issue":"3","key":"1607_CR4","first-page":"514","volume":"138","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Krueger JG. IL-23: a key cytokine in psoriasis pathogenesis. J Invest Dermatol. 2018;138(3):514\u20136.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1607_CR5","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, et\u00a0al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10091","key":"1607_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et\u00a0al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"1","key":"1607_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et\u00a0al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1607_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000519924","volume":"238","author":"KA Drerup","year":"2022","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615\u20139.","journal-title":"Dermatology"},{"issue":"6","key":"1607_CR9","volume":"34","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Llamas M, Rivera R, Juli\u00e0-Manresa M, Peris K, et\u00a0al. Tildrakizumab in moderate-to-severe psoriasis: real-life multicenter study focusing on metabolic comorbidities. Dermatol Ther. 2021;34(6):e15118.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1607_CR10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/jcm11051328","volume":"11","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Armario-Hita J, et\u00a0al. Real-world effectiveness and safety of tildrakizumab in Spanish patients. J Clin Med. 2022;11(5):1328.","journal-title":"J Clin Med"},{"issue":"8","key":"1607_CR11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/jdv.18184","volume":"36","author":"M Gal\u00e1n-Guti\u00e9rrez","year":"2022","unstructured":"Gal\u00e1n-Guti\u00e9rrez M, et\u00a0al. Real-world experience with tildrakizumab: 52-week results from a Spanish multicenter cohort. J Eur Acad Dermatol Venereol. 2022;36(8):1342\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1607_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jdv.19468","volume":"37","author":"S Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Herranz-Pinto P, et\u00a0al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37(12):2517\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1607_CR13","first-page":"e161","volume":"37","author":"L Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz L, Salvador-Rodriguez L, Ruiz-Villaverde R, Molina-Leyva A. Effectiveness and safety of tildrakizumab for psoriasis: retrospective multicenter study. J Eur Acad Dermatol Venereol. 2023;37(2):e161\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1607_CR14","doi-asserted-by":"publisher","first-page":"T722","DOI":"10.1016\/j.ad.2024.05.004","volume":"115","author":"MJ Melgosa-Ramos","year":"2024","unstructured":"Melgosa-Ramos MJ, Mateu-Puchades A, Mat\u00e1ix-D\u00edaz J, et\u00a0al. Eficacia a medio plazo (52 semanas) de tildrakizumab en el tratamiento de la psoriasis moderada a severa: un estudio multic\u00e9ntrico de pr\u00e1ctica cl\u00ednica. Actas Dermosifiliogr. 2024;115:T722\u20136.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1607_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/life15050789","volume":"15","author":"R Santos-Juanes","year":"2025","unstructured":"Santos-Juanes R, et\u00a0al. Tildrakizumab for psoriasis: real-world drug survival in a Spanish multicenter cohort. Life. 2025;15(5):789.","journal-title":"Life"},{"issue":"6","key":"1607_CR16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","volume":"154","author":"K Reich","year":"2006","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et\u00a0al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07237.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1607_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138. https:\/\/doi.org\/10.1111\/bjd.18245.","journal-title":"Br J Dermatol"},{"key":"1607_CR18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Picone V, Martora F, et\u00a0al. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649\u201358.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"1607_CR19","first-page":"234","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, et\u00a0al. Tildrakizumab effectiveness and drug survival in a large Italian real-world cohort. J Eur Acad Dermatol Venereol. 2023;37(2):234\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1607_CR20","first-page":"1419","volume":"37","author":"A Burmester","year":"2023","unstructured":"Burmester A, Wilsmann-Theis D, K\u00f6rber A, Radtke M, Mrowietz U. Real-life effectiveness and safety of tildrakizumab: interim analysis from the German TILOT study. J Eur Acad Dermatol Venereol. 2023;37(7):1419\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1607_CR21","first-page":"2104","volume":"36","author":"M Burlando","year":"2022","unstructured":"Burlando M, et\u00a0al. Tildrakizumab in real-life practice: updated Italian multicenter results at 52 weeks. J Eur Acad Dermatol Venereol. 2022;36(12):2104\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1607_CR22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/jcm11061693","volume":"11","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, D\u2019Adamio S, Campione E, et\u00a0al. Real-life experience with tildrakizumab: results from an Italian cohort. J Clin Med. 2022;11(6):1693.","journal-title":"J Clin Med"},{"issue":"5","key":"1607_CR23","first-page":"830","volume":"36","author":"A Gambardella","year":"2022","unstructured":"Gambardella A, et\u00a0al. Real-world effectiveness and safety of tildrakizumab: 52-week results from an Italian multicenter study. J Eur Acad Dermatol Venereol. 2022;36(5):830\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1607_CR24","first-page":"2012","volume":"36","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et\u00a0al. Long-term effectiveness and safety of tildrakizumab in psoriasis: real-world evidence from an Italian multicenter cohort. J Eur Acad Dermatol Venereol. 2022;36(11):2012\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1607_CR25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/ph16010132","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, et\u00a0al. Tildrakizumab for psoriasis: real-life 36-week results. Pharmaceuticals. 2023;16(1):132.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"1607_CR26","first-page":"e547","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Chiricozzi A, Dapavo P, De Simone C, Fargnoli MC, Micali G, et\u00a0al. Tildrakizumab improves high burden symptoms and quality of life: 52-week results from the Italian TRIBUTE study. J Eur Acad Dermatol Venereol. 2023;37(5):e547\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1607_CR27","first-page":"1517","volume":"36","author":"K Drerup","year":"2022","unstructured":"Drerup K, et\u00a0al. Real-world effectiveness of tildrakizumab in Germany: 60-week outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1517\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1607_CR28","first-page":"993","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, et\u00a0al. Tildrakizumab for psoriasis: real-life outcomes from Germany. J Eur Acad Dermatol Venereol. 2023;37(5):993\u20131001.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1607_CR29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jdv.18174","volume":"36","author":"G Licata","year":"2022","unstructured":"Licata G, Mastorino L, et\u00a0al. Long-term real-world data on tildrakizumab in psoriasis: a 96-week Italian multicenter study. J Eur Acad Dermatol Venereol. 2022;36(10):1745\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1607_CR30","first-page":"50","volume":"27","author":"F Bardazzi","year":"2023","unstructured":"Bardazzi F, et\u00a0al. Real-life data on tildrakizumab: high rates of skin clearance in an Italian multicenter cohort. J Cutan Med Surg. 2023;27(1):50\u20137.","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"1607_CR31","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s13555-025-01442-x","volume":"15","author":"E Trovato","year":"2025","unstructured":"Trovato E, Bianchelli T, Odorici G, et\u00a0al. Effectiveness of Tildrakizumab 200 mg in moderate-to-severe plaque psoriasis: a multicenter real-world study analyzing patient outcomes by weight, PASI, BMI, and previous therapies. Dermatol Ther (Heidelb). 2025;15(7):1941\u201352.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1607_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13555-025-01339-9","volume":"15","author":"F Diotallevi","year":"2025","unstructured":"Diotallevi F, Esposito M, Fargnoli MC, et\u00a0al. Real-life experience with Tildrakizumab in plaque psoriasis with palmoplantar involvement: a multi-center retrospective Italian study. Dermatol Ther (Heidelb). 2025;15(2):323\u201336.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1607_CR33","first-page":"1635","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, et\u00a0al. Real-world data on tildrakizumab in moderate-to-severe psoriasis: a 12-week German cohort. Dermatol Ther (Heidelb). 2022;12(7):1635\u201345.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1607_CR34","first-page":"1149","volume":"36","author":"A Brunasso","year":"2022","unstructured":"Brunasso A, et\u00a0al. Tildrakizumab in real-world management of psoriasis: 52-week outcomes. J Eur Acad Dermatol Venereol. 2022;36(7):1149\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1607_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2438803","volume":"36","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Tha\u00e7i D. Interleukin-23p19 inhibitors for psoriasis: expert opinion of real-world studies in Europe. J Dermatolog Treat. 2025;36(1):2438803.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1607_CR36","first-page":"e40","volume":"34","author":"P De la Cueva","year":"2023","unstructured":"De la Cueva P, Puig L, Mrowietz U, Warren RB, Gooderham M, Strohal R, et\u00a0al. Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. J Dermatolog Treat. 2023;34(1):e40\u20137.","journal-title":"J Dermatolog Treat"},{"key":"1607_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/24755303221077211","volume":"7","author":"NW Wei","year":"2022","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7:55\u20139.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"9","key":"1607_CR38","first-page":"e700","volume":"36","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Licata G, Campione E, et\u00a0al. Efficacy and safety of tildrakizumab: an Italian real-world 40-week study. J Eur Acad Dermatol Venereol. 2022;36(9):e700\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1607_CR39","first-page":"e859","volume":"35","author":"M Burlando","year":"2021","unstructured":"Burlando M, Carmisciano L, Cozzani E, Parodi A. Real-life effectiveness and safety of tildrakizumab for psoriasis: an Italian multicenter study. J Eur Acad Dermatol Venereol. 2021;35(12):e859\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1607_CR40","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.1402a53","volume":"13","author":"EV Di Brizzi","year":"2023","unstructured":"Di Brizzi EV, et\u00a0al. Short-term real-world outcomes with tildrakizumab in psoriasis: a 28-week study. Dermatol Pract Concept. 2023;13(2):e2023122.","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"1607_CR41","first-page":"2121","volume":"34","author":"CDB Elgaard","year":"2023","unstructured":"Elgaard CDB, et\u00a0al. Real-world effectiveness of tildrakizumab in Danish patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2023;34(5):2121\u20136.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1607_CR42","first-page":"1123","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, et\u00a0al. Real-world evidence on tildrakizumab: efficacy and safety at 52 weeks. J Eur Acad Dermatol Venereol. 2023;37(6):1123\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1607_CR43","doi-asserted-by":"crossref","unstructured":"Torres T, Varela P, Mendes Bastos P, Magina S, Henrique M, Ferreira P. Tildrakizumab for moderate-to-severe psoriasis: 52-week Portuguese multicentric study. Drugs Context. 2024;13:2023-12-5.","DOI":"10.7573\/dic.2023-12-5"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01607-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:37Z","timestamp":1770190837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01607-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rosa Izu Belloso, Isabel Gainza Apraiz, Mikel Meruelo Ruano, Irene Arevalo Ortega, Belen Navajas Pinedo, Ana Orbea Sope\u00f1a, Manuel Pascual Ares, Ana Mart\u00ednez-Buil, Gadea Braceras Rinc\u00f3n, Itziar Arrue Michelena, Ricardo Gonz\u00e1lez Perez, Bego\u00f1a Ramos Bare\u00f1o, and Ana Martinez de Salinas Quintana have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the local ethics committee (Code CEIm-E EOM2021048) and conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}